Connect with us


Ohio pharmacy board withdraws rule prohibiting hydroxychloroquine to treat COVID-19 Staff




Hours after Gov. Mike DeWine asked the Ohio Board of Pharmacy and the State Medical Board to halt a new rule issued Thursday that banned the use of hydroxychloroquine to treat COVID-19, the state pharmacy board has withdrawn the rule.

“As a result of the feedback received by the medical and patient community and at the request of Governor DeWine, the State of Ohio Board of Pharmacy has withdrawn proposed rule 4729:5-5-21 of the Administrative Code,” a news release from the board said.

“Therefore, prohibitions on the prescribing of chloroquine and hydroxychloroquine in Ohio for the treatment of COVID-19 will not take effect at this time.”

DeWine said he agrees with Dr. Steven Hahn, Commissioner of the U.S. Food and Drug Administration (FDA), that the decision about prescribing hydroxychloroquine to treat COVID-19 should be between a doctor and a patient.

Hydroxychloroquine has been touted as a treatment and preventative for COVID-19 by President Donald Trump and others, including Brazilian President Jair Bolsonaro.

But emerging scientific evidence suggests the drug, which is approved for the treatment of malaria and other conditions like rheumatoid arthritis, is not effective against COVID-19 and could even cause serious side effects, according to the FDA.

Get the latest news and updates delivered to your inbox.

Sign Up For Free